ClinicalTrials.Veeva

Menu

Prospective Multicenter Nationwide Registry of Children With Eosinophilic Esophagitis (RENESE)

S

Sociedad Espanola de Gastroenterologia, Hepatologia y Nutricion Pediatrica

Status

Unknown

Conditions

Eosinophilic Esophagitis

Treatments

Other: no intervention

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

  1. Registry of demographic, clinical, endoscopic and histological data at baseline.

  2. Registry of patients treated with PPI:

    • Clinical, endoscopic and histological response at 8-12 weeks of induction treatment
    • Clinical, endoscopic and histological response at 6 and 12 months weeks of maintenance treatment
  3. Registry of patients treated with two foods elimination diet:

    • Clinical, endoscopic and histological response at 8-12 weeks of induction treatment
    • Identification of food trigger: milk, gluten or milk and gluten
    • Clinical, endoscopic and histological response at one year elimination of food trigger
    • Registry of adverse events
  4. Registry of patients treated with swallowed steroids (budesonide or fluticasone):

    • Clinical, endoscopic and histological response at 8-12 weeks of induction treatment
    • Clinical, endoscopic and histological response at 6 months of maintenance steroid treatment
    • Registry of adverse events

Enrollment

500 estimated patients

Sex

All

Ages

1 month to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis (EoE) according to the recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus > 15 eos / CGA)
  • And that they need to start treatment with any of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids .

Exclusion criteria

  • Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis)
  • Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids).

Trial design

500 participants in 1 patient group

Children with eosinophilic esophagitis
Description:
Inclusion criteria: * Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus \> 15 eos / CGA) * And they need to start treatment with one of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids Exclusion criteria: * Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis) * Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids).
Treatment:
Other: no intervention

Trial contacts and locations

1

Loading...

Central trial contact

Belén Ruiz-Antorán, MD, PHD; Carolina Gutierrez-Junquera, MD, PHD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems